Breakthrough in the treatment of nausea and vomiting of pregnancy; the first dual release combination of doxylamine-pyridoxine

Gideon Koren, Manon Vranderick

Abstract


Nausea and vomiting of pregnancy (NVP) affect up to 85 % of all pregnancies. Effective treatment can improve  woman’s quality of life, reduce the risk for maternal and fetal complications, and reduce healthcare costs. Because women tend to date to postpone the start of their family into their thirties, increasing numbers of them suffer from chronic conditions necessitating internal medicine specialists, and hence NVP is increasingly a clinical issue the internist needs to deal with. The only agent approved by the FDA and other countries for the management of NVP symptoms and recommended by leading healthcare and professional organizations, has been the delayed release combination of doxylamine and pyridoxine. This combination, formulated as a 10 mg/10 mg delayed release tablet, was approved by the US Food and Drug Administration (FDA) for the treatment of NVP in April 2013 (Diclegis® ).  

Due to its delayed release properties, Diclegis® begins to exert its antiemetic properties 6-8 hours after ingestion, and hence symptom relief may be delayed and necessitate the use of an immediate release medication. In November 2016 the FDA approved Bonjesta®, a novel, dual- release combination of doxylamine and pyridoxine, whereby a rapid release phase is followed by a delayed release phase, thus overcoming the time delay in action of Diclegis® . In this article we review the unique properties of this new drug which is only the second FDA- approved agent for the treatment of NVP.

 

 

 


Keywords


nausea and vomiting of pregnancy, doxylamine, pyridoxine, Bonjesta, antiemetic drugs

Full Text:

 Subscribers Only

References


Lacroix R, Eason E, Melzack R. Nausea and vomiting during pregnancy: a prospective study of its frequency, intensity, and patterns of change. Am J Obstet Gynecol. 2000;182(4):931–7.

Clark SM, Costantine MM, Hankins GD. Review of NVP and HG

and early pharmacotherapeutic intervention. Obstet Gynecol Int. 2012;252676(10):24.

APGO. Nausea and vomiting of pregnancy. APGO Educational series on women’s health issues. Boston: Jespersen & Associates, LLC; 2013.

Goodwin TM. Hyperemesis gravidarum. Obstet Gynecol Clin North Am. 2008;35(3):401–17.

Golberg D, Szilagyi A, Graves L. Hyperemesis gravidarum and Helicobacter pylori infection: a systematic review. Obstet Gynecol. 2007;110(3):695–703.

Sandven I, Abdelnoor M, Nesheim BI, Melby KK. Helicobacter pylori infection and hyperemesis gravidarum: a systematic review and meta-analysis of case–control studies. Acta Obstet Gynecol Scand. 2009;88(11):1190–200.

Vikanes AV, Stoer NC, Gunnes N, Grjibovski AM, Samuelsen SO, Magnus P, et al. Helicobacter pylori infection and severe hyperemesis gravidarum among immigrant women in Norway: a case–control study. Eur J Obstet Gynecol Reprod Biol. 2013;167(1):41–6.

Fejzo MS, Macgibbon KW, Romero R, Goodwin TM, Mullin PM. Recurrence risk of hyperemesis gravidarum. J Midwifery Womens Health. 2011;56(2):132–6. 9. Fejzo MS, Ingles SA, Wilson M, Wang W, MacGibbon K, Romero R, et al. High prevalence of severe nausea and vomiting ofmpregnancy and hyperemesis gravidarum among relatives of

affected individuals. Eur J Obstet Gynecol Reprod Biol.2008;141(1):13–7.

Koren G, Maltepe C. Pre-emptive therapy for severe nausea and vomiting of pregnancy and hyperemesis gravidarum. J Obstet Gynaecol. 2004;24(5):530–3.

Maltepe C1, Koren G. Preemptive treatment of nausea and vomiting of pregnancy: results of a randomized controlled trial. Obstet Gynecol Int. 2013;2013:809787. doi: 10.1155/2013/809787. Epub 2013 Feb 17.

. Attard CL, Kohli MA, Coleman S, Bradley C, Hux M, Atanackovic G, et al. The burden of illness of severe nausea and vomiting of pregnancy in the United States. Am J Obstet Gynecol.

;186(5 Suppl Understanding):S220–7.

Lacasse A, Rey E, Ferreira E, Morin C, Berard A. Nausea and vomiting of pregnancy: what about quality of life? Bjog. 2008;115(12):1484–93.

Nguyen P, Einarson A. Managing nausea and vomiting of pregnancy with pharmacological and nonpharmacological treatments. Women’s health (London, England). 2006;2(5):753–60.

. Miller F. Nausea and vomiting in pregnancy: the problem of perception—is it really a disease? Am J Obstet Gynecol. 2002;186(5 Suppl Understanding):S182–3.

. Mazzotta P, Stewart DE, Koren G, Magee LA. Factors associated with elective termination of pregnancy among Canadian and American women with nausea and vomiting of pregnancy.

J Psychosom Obstet Gynaecol. 2001;22(1):7–12.

. Piwko C, Ungar WJ, Einarson TR, Wolpin J, Koren G. The weekly cost of nausea and vomiting of pregnancy for women calling the Toronto Motherisk Program. Curr Med Res Opin.

;23(4):833–40.

. Piwko C, Koren G, Babashov V, Vicente C, Einarson TR. Economic burden of nausea and vomiting of pregnancy in the USA. J Popul Ther Clin Pharmacol. 2013;20(2):10.

Einarson A, Maltepe C, Boskovic R, Koren G. Treatment of nausea and vomiting in pregnancy: an updated algorithm. Can Fam Physician. 2007;53(12):2109–11.

Jewell D, Young G. Interventions for nausea and vomiting in early pregnancy. Cochrane Database Syst Rev. 2003;4: CD000145.

Scorza K, Williams A, Phillips JD, Shaw J. Evaluation of nausea and vomiting. Am Fam Physician. 2007;76(1):76–84.

Gill SK, Einarson A. The safety of drugs for the treatment of nausea and vomiting of pregnancy. Expert Opin Drug Saf. 2007;6(6):685–94.

Brent RL. Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen–litigen. Reprod Toxicol. 1995;9(4):337–49.

Einarson TR, Leeder JS, Koren G. A method for meta-analysis of epidemiological studies. Drug Intell Clin Pharm. 1988;22(10): 813–24.

McKeigue PM, Lamm SH, Linn S, Kutcher JS. Bendectin and birth defects: I. A meta analysis of the epidemiologic studies. Teratology. 1994;50(1):27–37.

Magee LA, Mazzotta P, Koren G. Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obstet Gynecol. 2002;186(5 Suppl Understanding):S256–61.

Koren G, Clark S, Hankins GD, Caritis SN, Miodovnik M, Umans JG, et al. Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized

placebo controlled trial. Am J Obstet Gynecol. 2010;203(6):16.

ACOG. ACOG (American College of Obstetrics and Gynecology) practice bulletin: nausea and vomiting of pregnancy. Obstet Gynecol. 2004;103(4):803–14.

SOGC. Clinical practice guidelines. The management of nausea and vomiting of pregnancy. J Obstet Gynaecol Can. 2002;24(10):817–23.

MothertoBaby. Nausea and vomiting. In: Maternal medical conditions fact sheets. http://www.mothertobaby.org/files/ Nausea_and_Vomiting_7_13_2.pdf. 2013.

http://www.bendectin.com. Accessed: October 01, 2013.

Brent R. Bendectin and birth defects: hopefully, the final chapter. Birth Defects Res A Clin Mol Teratol. 2003;67(2):79–87.

Kutcher JS, Engle A, Firth J, Lamm SH. Bendectin and birth

defects. II: ecological analyses. Birth Defects Res A Clin Mol Teratol. 2003;67(2):88–97.

Bendectin Peer Review Report 1975. Overall summary of 8-way Bendectin Study (unpublished study from the FDA databan DESI-10598). FDA1975 Contract No.: DESI 10598.

Martindale: The complete drug reference. 37th ed. Database on the internet. London: Pharmaceutical Press; 2011.51. Ottawa TCPA. Compendium of pharmaceuticals and specialties. Ottawa,ON. 2013. http://www.pharmacists.ca/index.cfm/educationpractice- resources/canadian-drug-therapeutic-information/errata/ errata-cps/#cps2013.

Geiger CJ, Fahrenbach DM, Healey FJ. Bendectin in the treatment of nausea and vomiting in pregnancy. Obstet Gynecol. 1959;14:688–90.

McGuinness BW, Binns DT. ‘Debendox’ in pregnancy sickness. J R Coll Gen Pract. 1971;21(109):500–3.

Wheatley D. Treatment of pregnancy sickness. Br J Obstet Gynaecol. 1977;84(6):444–7.

Bishai R, Mazzotta P, Atanackovic G, Levichek Z, Pole M, Magee LA, et al. Critical appraisal of drug therapy for nausea and vomiting of pregnancy: II. Efficacy and safety of Diclectin (doxylamine-B6). Can J Clin Pharmacol. 2000;7(3):138–43.

Neutel CI, Johansen HL. Measuring drug effectiveness by default: the case of Bendectin. Can J Public Health. 1995;86(1):66–70.

Duchesnay Inc. Bonjesta Full Prescribing Information. Blainville, Quebec, Canada. 2016

Costantine MM, Matok I, Chiossi G, et al. Determinants of Adherence to Delayed-Release Doxylamine and Pyridoxine in Patients With Nausea and Vomiting of Pregnancy. Ther Drug Monit 2012;34:569-73.

Food and Drug Administration. Center for Drug Evaluation and Research: NDA 209661, Summary Review. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209661Orig1s000SumR.pdf. November 7, 2016.

GlaxoSmithKline. Zofran Full Prescribing Information. Research Triangle Park, NC, United States. October 2016.

Sandoz Inc. Promethazine Hydrochloride Full Prescribing Information. Princeton, NJ, United States. April 2014.




DOI: http://dx.doi.org/10.18103/imr.v4i4.698

Refbacks

  • There are currently no refbacks.
Copyright 2016. All rights reserved.